Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2024 Earnings Call Transcript

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2024 Earnings Call Transcript November 13, 2024

Operator: Good morning, and welcome to Fulcrum Therapeutics Third Quarter 2024 Financial Results and Business Update Conference Call. Currently, all participants are in a listen-only mode. This call is being webcast live and can be accessed on the Investors section of Fulcrum’s website at www.fulcrumtx.com and is being recorded. Please be reminded that remarks during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. And may include statements about the company’s future expectations and plans, clinical development time lines and financial projections. While these forward-looking statements represent Fulcrum’s views as of today, this should not be relied upon as representing the company’s views in the future.

Fulcrum may update these statements in the future, but is not taking on an obligation to do so. Please refer to Fulcrum’s most recent filings with the Securities and Exchange Commission for discussions of certain risks and uncertainties associated with the company’s business. Leading the call today will be Alex Sapir, CEO and President of Fulcrum. Joining Alex on the call are Alan Musso, Chief Financial Officer; Dr. Pat Horn, Chief Medical Officer; and Dr. Iain Fraser, Senior Vice President of Development. After providing updates on our key programs, there will be a brief Q&A, in which Alex, Alan, Pat and Iain will be available to answer your questions. With that, it’s my pleasure to turn the call over to Alex.

Alex Sapir: That’s great. Thanks, Michelle, and good morning, everyone. I appreciate you joining us for our third quarter conference call. Today, I’ll provide you with updates on recent progress and upcoming milestones. I’ll then hand the call over to Alan to review financials. And finally, we’ll end by taking your questions. I’ll begin with a very brief review of the update we provided on the losmapimod program back in September. As you’ll recall, we reported that losmapimod did not show separation from the placebo group on the primary or key secondary endpoints in the Phase 3 REACH trial. In light of these results, we suspended the development of losmapimod and announced a workforce reduction of approximately 40% in order to focus our research and development efforts on advancing pociredir and our preclinical pipeline.

This included a reduction of positions across both research and development as well as general and administrative functions. I do want to take a moment to express my gratitude to the patients, physicians and clinical coordinators, who participated in our trials, to the FSHD Society and to the broader FSHD community. We sincerely appreciate all of your support in advancing the losmapimod program, and we remain fully committed to sharing the full results of the REACH trial for the benefit of the FSHD community. Although we were disappointed that the Phase 3 results did not replicate what was shown in Phase 2, the entire Fulcrum organization remains deeply committed to our mission of improving the lives of patients with genetically defined diseases in areas of high unmet need.

To that end, we are excited to continue advancing pociredir, our oral HbF inducer, for the potential treatment of patients with sickle cell disease. Sickle cell disease is a lifelong inherited blood disorder that severely impacts quality of life for approximately 100,000 people in the U.S. and approximately 4.4 million people worldwide. Historically, the standard of treatment for patients with sickle cell disease has involved blood transfusions, pain medications and hydroxyurea, focusing primarily on symptom relief. Despite the recent approval of gene editing approaches, we believe there remains a significant unmet need for safe and accessible oral therapeutic options that are broadly protective of sickle cell symptomatology, which is further underscored by the recent global withdrawal of OXBRYTA.

As a first-in-class oral small molecule HbF inducer, we believe that pociredir has the potential to address this unmet need. Now in our Phase 1b trial of pociredir, which we call the PIONEER trial, we continue to make progress enrolling patients and activating sites. We are focused on progressing the development of pociredir as expeditiously as possible and remain on track to provide data from the PIONEER trial in 2025. Based on our progress in site activation and current enrollment trends, we intend to provide more detailed guidance on our plans to share data early in the new year. As a reminder, Cohort 3 of the trial is evaluating pociredir at the 12-milligram once daily dose with a dosing duration of three months, and this will be followed by Cohort 4 at the 20-milligram once-daily dose also for three months.

Both cohorts are expected to enroll up to 10 patients. In addition to the ongoing PIONEER trial, we are also pleased to report that we are initiating Phase 1 clinical trials of pociredir in healthy volunteers following recent interactions with the FDA. These studies are intended to support the comprehensive development program for pociredir. The literature supports that any increase in fetal hemoglobin is beneficial for patients with sickle cell disease. And most importantly, when sickle cell patients achieve fetal hemoglobin levels in the mid to high-20s, their disease presentation may become asymptomatic. We believe that as a novel inducer of fetal hemoglobin, pociredir has the potential to provide a differentiated therapeutic option for people living with sickle cell disease.

We look forward to building on the encouraging clinical data generated prior to the hold, which demonstrated that pociredir increased total fetal hemoglobin of a magnitude that could translate into meaningful improvements in disease severity. Now beyond pociredir, we are also focused on advancing our early stage development programs in inherited aplastic anemia, such as Diamond-Blackfan anemia, or DBA, Schwachman-Diamond syndrome, or SDS and Fanconi anemia, under our licensing agreement with CAMP4. We anticipate sharing additional information regarding a development candidate and plan for IND-enabling studies in the near future. I also wanted to provide some updates on the management and Board of Directors front. This morning, we announced that Rachel King has joined our Board of Directors, having served as the CEO at BIO, Executive in Residence at NEA as well as CEO of several early-stage biotech companies.

Rachel’s experience is well aligned with Fulcrum’s needs given where we are in our evolution. She currently serves on the Board of Novavax and GlycoMimetics. Rachel will be replacing Jim Collins, who will be transitioning to an advisory role on our Science and Technology Committee. I’m personally excited to have Rachel joining us and also pleased that we will continue to benefit from Jim’s deep scientific acumen and sound judgment. Now on the management front, Dr. Thomas Winkler joined us in September as our Vice President of Hematology Clinical Development and has assumed responsibility for our hematology program, but also for the PIONEER study. Thomas has a distinguished career within the hematology branch of the NIH before transitioning to industry, where he focused on developing numerous hematology assets at both Agios and AstraZeneca.

Additionally, Pat Horn, our Chief Medical Officer, has decided to retire at the end of this year. Pat joined Fulcrum earlier this year and was instrumental in leading clinical development for the REACH study, hiring key talent, like Thomas, and building out the medical team as we prepare for the launch of losmapimod. I would like to personally thank Pat, who is here with us in the room today. Thank you, Pat, as well as express my appreciation to Thomas for bringing his strong hematology background to Fulcrum at such a critical time. And with that, I will now turn it over to our Chief Financial Officer, Alan Musso, to run through the numbers. Alan, over to you.

Alan Musso: Thanks, Alex. I’ll now review our financial results, starting with our cash position. As of September 30, 2024, cash, cash equivalents and marketable securities were $257.2 million compared to $236.2 million as of December 31, 2023. The increase in our cash position is due to the $80 million upfront payment that we received from Sanofi in the second quarter, partially offset by cash used to fund our operating activities in 2024. We had no collaboration revenue in the third quarter of 2024, compared to $0.8 million for the third quarter of 2023. The decrease of $800,000 was due to the completion of our research services under our collaboration agreement with MyoKardia during the fourth quarter of 2023. Our research and development expenses were $14.6 million for the third quarter of 2024 compared to $18.2 million for the third quarter of 2023.

The decrease of $3.6 million was primarily due to the global development cost sharing reimbursement under our collaboration with Sanofi for losmapimod, partially offset by increased costs related to the advancement of our Phase 1b PIONEER trial. General and administrative expenses were $8.4 million for the third quarter of 2024 compared to $10 million for the third quarter of 2023. The decrease of $1.6 million was primarily due to decreased employee compensation costs as a result of our reduction in workforce implemented in the third quarter of 2024. The net loss of $21.7 million for the third quarter of 2024 compared to a net loss of $24 million for the third quarter of 2023. Finally, turning to our cash guidance. We expect to end 2024 with approximately $240 million of cash, cash equivalents and marketable securities, and we expect that in 2025, our cash burn will be approximately $55 million to $65 million.

Based on current operating plans, we expect that our current — our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating requirements into at least 2027. And with that, let me turn the call back over to you, Alex.

Alex Sapir: Okay. Great. Thanks so much, Alan. And I think with that overview of the business and the financials, Michelle, why don’t we go ahead and open it up for questions.

Q&A Session

Operator: Thank you. [Operator Instructions] And our first question will come from Matthew Biegler with Oppenheimer. Your line is now open.

Matthew Biegler: Hey, guys. Thanks for the update this morning. Maybe just a high-level question, Alex, on the platform tech and how you’re thinking of seat in the pipeline with new wholly-owned assets. How do you think about the difference between keeping it wholly-owned versus partnering something out? And for maybe next-gen assets, are there certain disease therapeutic areas that you want to focus in? I mean, should the focus be hematology going forward? Or are you kind of open to exploring new avenues? Thanks.

Alex Sapir: Yes. It’s great, Matt. Thanks so much for the question. Yes, so we do have a very rich preclinical pipeline. I would say that the most advanced preclinical program that we have, as I mentioned during the prepared remarks, is our program that we have for inherited aplastic anemias, which do include DBA, Schwachman-Diamond syndrome, or SDS, Fanconi anemia 5Q syndrome. And we do expect to announce more updates in the near future around the selection of a development candidate and IND-enabling study. So that is by far our most advanced program. And as you know, [Technical Difficulty] came from the deal that we signed with CAMP4 in September of last year. We do have the global rights for those. I think for the time being, we are going to continue to progress those ourselves.

And then obviously, there is always an option for potential licensing for potentially markets outside of the U.S., similar to what we did with the with the Sanofi deal with losmapimod. But right now, our focus is really on progressing some very, very interesting work that we’ve got going on in our discovery efforts. Most notable is the work we’re doing in some of these inherited aplastic anemias that I mentioned. Iain, anything you would add to that?

Iain Fraser: No, I think that covers around pretty comprehensively.

Matthew Biegler: Okay. Thanks guys, appreciate it.

Alex Sapir: Yes, thanks Matt.

Operator: And our next question will come from Dae Gon Ha with Stifel. Your line is open.

Dae Gon Ha: Great. Good morning, guys. Thanks for taking our questions and congrats on the progress. Congrats on the progress. I guess two questions on pociredir, specifically. Going back to your 10-Q filing, it seems like on the Risks section, you have been having this information or the language around request for information to define a potential risk in any further studies that may be conducted in healthy volunteers. You are announcing your intention to do another healthy volunteer study. So curious what exactly was the feedback from the FDA post OXBRYTA withdrawal that led you to having this trial run sort of concurrent with the PIONEER study. And then second, I guess, in terms of the African conduct, just curious what have been sort of the latest FDA feedback on whether or not that meets the standards for the FDA review?

Alex Sapir: Sure. Yes. Thanks, Dae Gon, so much for the question. And I’ll probably — I’ll add a little bit of color on the first question, punt that over to Iain. And then as it relates to the second question around African content, I’ll punt that over to Pat. Yes, so I think just to remind everybody on the call, when we did get off clinical hold, there was no additional clinical or preclinical data that the FDA required prior to going into patients. There was some additional work that the FDA did require of us in order to progress with healthy volunteers. And based on the discussions that we’ve had with the agency, we are, as I mentioned in the prepared remarks, we are moving forward with the work that we need to do in healthy volunteers to really inform the overall clinical development plan and the eventual package that will become the NDA. But I think more specifically, let me turn that over to Iain, maybe to get into a little bit more detail.

Iain Fraser: Yes. Thanks, Alex. Thanks, Dae Gon. So I think important to recognize that these healthy volunteer studies were or studies that have been planned all along their part of the routine development of a compound. There are studies that look at evaluations of new formulations as they get introduced into the clinic, some of the drug-drug interaction studies and studies to more finally delineate the metabolism and excretion of the compound. So those are our standard drug development studies that were always part of the program. As Alex mentioned, there was this differentiation at the time of the clinical hold between the patient studies, and resuming patient studies was entirely around refining that patient population and balancing risk benefit.

And then on the healthy volunteer side was segregated out because, of course, there’s no benefit to individuals participating in healthy volunteer studies. And so we’ve performed those and are now progressing with the studies as part of the overall development plan. It’s really coincidental around the timing of the OXBRYTA withdrawal, and there’s no link between resumption of those studies and the OXBRYTA withdrawal.

Alex Sapir: Yes. And then, Dae Gon, as it relates to your second question before turning it over to Pat, I think maybe just really quickly, for some of the patients that we have enrolled to date, they are coming from African countries. And I will say that we’ve actually been pretty pleased with some of the compliance that we’ve seen to date. In terms of the regulatory take on patients coming from sites in Africa, maybe I’ll turn that one over to Pat to provide a little bit more detail.

Patrick Horn: Yes. So the FDA has a long history of accepting data from ex U.S. sites. In fact, most of the large Phase 3 studies now are global size and in diseases, such as sickle cell anemia, where the population is really concentrated in different geographies, there’s a long history. I think the majority of studies in sickle cells that have led to approval and that are currently ongoing in Phase 2 and Phase 3 have included sites in sub-Saharan Africa, especially. The FDA is really only concerned about the quality data and that they are followed GCP. And as part of our progress and ongoing activities in the study, we review each of these sites before we select sites that have experience. Most of them have experienced in previous sickle cell studies.

And most of the sites we’re looking at have been audited by regulatory agencies, some even by the FDA. So we feel confident in the sites we’ve selected and their ability to produce acceptable data for the Phase 1 study and then even for future registration studies.

Dae Gon Ha: Great. Thanks for taking our questions. Oh, sorry.

Alex Sapir: No worries, thanks, Dae Gon, thanks so much. Operator, next question.

Operator: And our next question will come from Edward Tenthoff with Piper Sandler. Your line is open.

Edward Tenthoff: Great. Good morning, everyone. Thanks for taking my question. So following up on Dae Gon’s questions, I wanted to get a little sense in terms of — can you provide any better guidance on how this data from PIONEER may roll out next year. Will you report it all together? Would you split the 12 mg and 20 mg and kind of reported as it’s available? And how quickly do you envision being able to transition from that into a registrational study?

Alex Sapir: Yes. That’s great, Ted. Thanks so much for asking the question. I’ll address the first part of your question, and then I’ll turn it over to Pat to address the second part of your question. Yes, so as we’ve said in the past, we do intend to share the 12-milligram cohort, which is being run sequential to the 20 milligram. So those 2 data sets will come out at different points in time in 2025. And so we do intend to share those independent of one another. We are pleased with the progress that we are seeing right now with enrollment. We absolutely have the right sites that are now in place, and we’re continuing to add new sites. And as we’ve always said, once we build that critical mass of patients, we’ll come back to everybody with more specificity, specifically when in 2025, we’ll have data to share.

So I think right now, it is a bit premature to give any more specific guidance. But as I said in some of my prepared remarks, we do intend to provide more detailed guidance on our plan to share data early in the new year, in early 2025. So I think more specifically about your question in terms of what’s the next study after this, maybe, I’ll turn that one over to Pat.

Patrick Horn: Yes. So Thomas Winkler, since he’s been here, he’s been working with our Head of Regulatory and our regulatory group to really define the clinical development program for pociredir following this Phase 1b, and there are multiple possibilities. Since we have Orphan Drug Designation, we are entitled to end the Phase 1 study with the FDA, which we plan to make use of. So we’ll take the data from the PIONEER study, take a — propose a clinical development plan to the FDA and then get their agreement. And that may be — that may be the ability to move quickly to a Phase 2, Phase 3 study, which may be registrational or it may be a separate Phase 2 followed by a Phase 3 study. But that will depend on the data from PIONEER and the feedback from the FDA.

Alex Sapir: Yes. And then, Ted, maybe the only other thing that I would add is the abundance of evidence to show that increases in fetal hemoglobin improves not only symptomatology in terms of reduction in VOCs, but also overall survival. And as we’ve said and shared with you many times, once you get patients over that sort of mid- to high 20s, their disease does become asymptomatic. So I think there’s certainly internal discussion going as well as to when is the right time to discuss fetal hemoglobin potentially as a surrogate endpoint that we may use in one of our further development — in one of our further studies for the Pioneer development program. So that’s — that work is still ongoing, but I think that is an important point to make just because how strongly the relationship is based on the data that is out there to show that increases in fetal hemoglobin have a very, very noticeable impact on survival as well as reduction in VOCs.

Edward Tenthoff: Yes, makes a lot of sense. Great. Thank you so much for the call. I look forward to seeing you in just a couple weeks here.

Alex Sapir: Yes, it’s great. Thanks so much, Ted. Operator, next question.

Operator: And our next question comes from Kristen Kluska with Cantor Fitzgerald. Your line is open.

Rick Miller: Hi, everyone. This is Rick Miller, on for Kristen. Just a quick follow-up on the healthy volunteer studies. You’ve talked about initiating. How are you thinking about dose in these trials? And how this relates to kind of the previous Phase 1 trial dosing strategies you looked at? And in terms of main outcomes here, will this be mostly looking at safety? Or are there any kind of PK/PD measures you’re interested in getting a look at?

Alex Sapir: Yes, it’s a great question, Rick. And I think to answer that, let me kick that one over to Iain.

Iain Fraser: Yes. Thanks, Rick. The studies are predominantly looking at PK profiles in this case, both from the perspective of the ADME, the absorption, distribution and metabolism of the drug. It’s a standard radiolabel study that gets done in development. So that’s one of the studies that’s teed up measuring the drug in the blood and the excretion in the urine and the stool, for example. And then the other studies are primarily focused on measuring the PK. So new formulations as they come into development will be given to healthy volunteers and typically single-dose PK studies, where you measure the performance of the new formulation and compared to the older formulation and for the drug-drug interaction studies is giving pociredir in the presence of other agents that are commonly used in order to evaluate any impact on the plasma pharmacokinetics of the drug.

So those are the studies that are in line as part of the overall development program and what we’ll be doing. We obviously look at safety and tolerability as a key endpoint in all of those studies, but the important driver of the results that goes back to inform the clinical program in the patients is around the PK.

Rick Miller: Thank you.

Alex Sapir: Yes, thanks Rick. Operator, next question.

Operator: And our next question comes from Greg Renza with RBC Capital. Your line is open.

Greg Renza: Great. Thanks. Good morning, Alex and team.

Alex Sapir: Good morning, Greg.

Greg Renza: Thanks for taking the questions. Just a couple from us, Alex, that just as you reflect on the losmapimod experience, how are you using that journey to inform the value proposition, the risk assessment of future programs, not just with pociredir, but also, of course, with the early discovery programs. And then maybe secondly, if you could just comment a bit about how you expect to balance the early discovery programs internally and with camp that you’re looking at versus the thought of looking externally for assets. And maybe I’ll sneak a third one, if I may, for Alan. Maybe related to all of this, as you’ve talked a bit about resources and spend for 2025. How does that allocation pan out? How should we be thinking about what’s implied in some of the runway there? Thanks so much guys.

Alex Sapir: Yes. Thanks so much, Greg. Great set of questions. Yes, so I think if we do a comparison in contrast of losmapimod versus pociredir, I think they are very different. I think some of the challenges that we knew going into the Phase 3 study with losmapimod is it was a new novel endpoint, and it was very effort dependent. I think what we see with pociredir and what we know about pociredir in terms of the patients that were enrolled in the study prior to the initiation of the hold and very impressive increases that we saw in fetal hemoglobin as well as the abundance of literature out there to show that increases in fetal hemoglobin have a direct impact on patients, crises as well as their overall survival. I think I see them as very sort of different development programs as we move forward.

And I think, as I mentioned earlier, after one of Pat’s last comments, we are having internal discussions. Given how strong the evidence is, we’ve been working very closely with some ex-FDA consultants to really understand, does it make sense or when is the right time to approach the agency and their surrogate endpoint group within the agency around the potential to use fetal hemoglobin as a surrogate endpoint. Obviously, the agency does have a history of approving other products in sickle cell disease using surrogate endpoints as we know. I think as you think about sort of early discovery versus externally, as Alan mentioned, we’ve got a very robust balance sheet into at least 2027, and that is assuming success with all of our programs. So that’s advancing the pociredir program once we completed this Phase 1b study into Phase 2 and Phase 3.

So we certainly have the financial ability to go out and look at external assets, but I think we’ve got a lot of really exciting things going on in early discovery. If we were to look externally at potentially opportunities to bring in-house, given how robust our balance sheet is, we’ll continue to be very judicious and highly selective. The company has had a history of doing deals, but those deals, I think, have been on excellent terms, and we’ve been very sort of smart and judicious in terms of what we decide to bring in. So if we were to do something, I think it would be at the level of sort of intelligence and just sort of deep diligence that we’ve historically done with other licensing opportunities of assets that we brought in. And then maybe Alan to answer his third question.

Alan Musso: Yes, Alex, I think you addressed some of it. Greg, as we guided, we expect next year’s spend to be $55 million to $65 million. And that does anticipate full funding of pociredir and maximizing the opportunity there and funding our preclinical programs and seeing those advance forward. So we feel like we’re fortunate to be in a really good shape with our cash position at this time.

Greg Renza: Great, thank you guys.

Alex Sapir: Yes, thanks Greg.

Operator: And our next question comes from Joseph Schwartz with Leerink. Your line is open.

Joori Park: Hi, I’m Joori Park, dialing in for Joe. Thanks for taking our question. So this summer at EHA, you presented a map of sites you were onboarding. And I believe there were 11 in the U.S. and two ex U.S. I was curious what your latest thoughts were on these sites? And then separately, I believe that you plan to activate up to 20 sites. That’s what you said on our previous call, with more sites to activate, which you’ve mentioned on today’s call. So I was curious if you’ve identified the remaining seven sites and where you are on the onboarding process for them. Thank you.

Alex Sapir: Yes, it’s a great question, and I’ll start and then I’ll turn it over to Pat to provide a little bit more detail. So yes, you are correct. We have 12 sites activated. I would say that some of the more recently activated sites, both here in the U.S. as well as the ex U.S. are absolutely the right sites that we — that are in place now. And again, pleased with some of the early insights we’re seeing in terms of patient enrollment. Our goal is still to ramp up and enroll 20 sites by the end of this year. We were at a — both Pat and I were at an investigator meeting in Dallas, just this past Friday, we had 15 sites represented, many of the existing sites, but also several new sites that will be activated in the coming months. But maybe, Pat, do you want to sort of give a little bit more specificity in terms of when we would expect to have those additional sites onboarded.

Patrick Horn: Yes. So we are actively working on activation, and we have — to your question, we have identified the sites that we believe will be successful in recruiting PIONEER. The majority of those are made in the U.S., but there are some in Africa, and we are working to activate all of those. We have activated — I don’t know the exact number, but many more since the EHA meeting, and we continue — we have in the next couple of months, we had the activation and site initiation visits planned for pretty much the remaining sites. We continue to — and like I said, we think these sites will be sufficient to enroll PIONEER. We continue to engage new sites and new investigators partly for future studies because there has been an increased interest in pociredir and hemoglobin F inducers.

So we continue to engage with new sites, and there’s a possibility that some of them if their activation could be quick enough, could also join and help with Pioneer. But it’s predominantly more for future studies.

Joori Park: Great. Thank you.

Alex Sapir: Yes, thanks so much for the question.

Operator: [Operator Instructions] And our next question comes from Corinne Johnson with Goldman Sachs. Your line is open.

Corinne Johnson: Good morning, everyone. You mentioned the pociredir program is fully funded. I guess does that apply to a broader scope of patients and is currently allowed within the trial? Or would that be specific to this higher risk group you’re currently focused on? Thanks.

Alex Sapir: Yes. So Corinne, maybe I’ll start, and then I’ll turn it over to Alan for more specifics in terms of the funding and what we’ve allocated. Yes, so as we’ve said in the past, we believe that once we’re able to show the benefits that based on the data that we had prior to the initiation of the hold with these additional 20 patients, we will be able to have a future conversation with the agency, as Pat mentioned, at the end of the Phase 1 program, to really look to expand the patient population beyond the more severe patient population that we are — that we’re currently targeting because I think obviously, for the agency, they’re thinking about everything from a risk benefit. And as we’ve talked about in some of our preclinical work, there was this carcinogenicity risk that was seen, that was really the impetus for the reason for the hold.

But there were also some of the impressive levels of fetal hemoglobin that we saw in the first 15 patients. So our goal is to get these additional 20 patients with this more severe patient population enrolled, have them complete their entire three months of dosing, take a look at that data and then approach the agency about expanding the patient population beyond where we are today. And then, Alan, in terms of the specifics around the funding and what that looks like and what the study looks like.

Alan Musso: Yes, Corinne. So we’re sort of budgeting and forecast process encompasses taking the development plans and in full as to where we expect the program will go not only next year, but beyond that and then allocating the capital towards that. So that’s the guidance that we give, which is sort of complete development anticipation for pociredir going forward.

Corinne Johnson: Okay. Thank you.

Alex Sapir: Thanks, Corinne.

Operator: I show no further questions at this time. This does conclude today’s conference call. Thank you so much for participating. You may now disconnect.